BACKGROUND: Inflammation is an important component of carcinogenesis but little research has been conducted on whether inflammation markers can be predictive of cancer risk in humans. METHODS: We analyzed C-reactive protein (CRP), a marker of inflammation, in plasma samples of 496 cases of cancer and 996 controls selected among participants in a prospective study from Greece. RESULTS: Plasma CRP level was higher in cancer cases than controls (odds ratio for increase in CRP level of 3.2 mg/L, 1.20; 95% confidence interval, 1.10-1.32): The corresponding odds ratio after exclusion of the first year of follow-up and of individuals with CRP level above 20 mg/L was 1.32 (95% confidence interval, 1.15-1.52). Although based on small number of cases, the association between elevated plasma CRP level and risk was stronger for cancers of the liver, lung, skin, kidney, and bladder, as well as for lymphoma and leukemia than for other neoplasms. CONCLUSIONS: Our results confirm the important role of inflammation in human cancer and suggest that plasma CRP level is a potential marker of increased cancer risk.
BACKGROUND:Inflammation is an important component of carcinogenesis but little research has been conducted on whether inflammation markers can be predictive of cancer risk in humans. METHODS: We analyzed C-reactive protein (CRP), a marker of inflammation, in plasma samples of 496 cases of cancer and 996 controls selected among participants in a prospective study from Greece. RESULTS: Plasma CRP level was higher in cancer cases than controls (odds ratio for increase in CRP level of 3.2 mg/L, 1.20; 95% confidence interval, 1.10-1.32): The corresponding odds ratio after exclusion of the first year of follow-up and of individuals with CRP level above 20 mg/L was 1.32 (95% confidence interval, 1.15-1.52). Although based on small number of cases, the association between elevated plasma CRP level and risk was stronger for cancers of the liver, lung, skin, kidney, and bladder, as well as for lymphoma and leukemia than for other neoplasms. CONCLUSIONS: Our results confirm the important role of inflammation in humancancer and suggest that plasma CRP level is a potential marker of increased cancer risk.
Authors: Mark P Purdue; Qing Lan; Rachel Bagni; William G Hocking; Dalsu Baris; Douglas J Reding; Nathaniel Rothman Journal: Cancer Res Date: 2011-06-01 Impact factor: 12.701
Authors: Andrew T Chan; Camelia S Sima; Ann G Zauber; Paul M Ridker; Ernest T Hawk; Monica M Bertagnolli Journal: Cancer Prev Res (Phila) Date: 2011-08
Authors: Tao Wang; Thomas E Rohan; Marc J Gunter; Xiaonan Xue; Jean Wactawski-Wende; Swapnil N Rajpathak; Mary Cushman; Howard D Strickler; Robert C Kaplan; Sylvia Wassertheil-Smoller; Philipp E Scherer; Gloria Y F Ho Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-03-17 Impact factor: 4.254
Authors: Jun Wang; I-Min Lee; Shelley S Tworoger; Julie E Buring; Paul M Ridker; Bernard Rosner; Susan E Hankinson Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-05-20 Impact factor: 4.254
Authors: Joshua Demb; Esther K Wei; Monika Izano; Stephen Kritchevsky; Helen Swede; Anne B Newman; Michael Shlipak; Tomi Akinyemiju; Steven Gregorich; Dejana Braithwaite Journal: J Geriatr Oncol Date: 2018-08-03 Impact factor: 3.599
Authors: Kyung A Kwon; Sung Hyun Kim; Sung Yong Oh; Suee Lee; Jin-Yeong Han; Kyeong Hee Kim; Ri Young Goh; Hong Jo Choi; Ki Jae Park; Mee Sook Roh; Hyo-Jin Kim; Hyuk-Chan Kwon; Jong Hoon Lee Journal: BMC Cancer Date: 2010-05-14 Impact factor: 4.430
Authors: Darren R Brenner; Dominique Scherer; Kenneth Muir; Joellen Schildkraut; Paolo Boffetta; Margaret R Spitz; Loic Le Marchand; Andrew T Chan; Ellen L Goode; Cornelia M Ulrich; Rayjean J Hung Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-06-24 Impact factor: 4.254